Copyright
©The Author(s) 2016.
World J Gastroenterol. Apr 7, 2016; 22(13): 3632-3643
Published online Apr 7, 2016. doi: 10.3748/wjg.v22.i13.3632
Published online Apr 7, 2016. doi: 10.3748/wjg.v22.i13.3632
Table 4 Adverse events related to sorafenib administration n (%)
| Adverse event | Mono-therapy of sorafenib | TACE combined with sorafenib | ||||
| All events | Grade 1-2 events | Grade 3-4 events | All events | Grade 1-2 events | Grade 3-4 events | |
| Overall incidence | 14 (93.3) | 12 (80.0) | 2 (13.3) | 30 (90.9) | 26 (78.8) | 4 (12.1) |
| Alopecia | 6 (40.0) | 6 (40.0) | 0 (0.0) | 11 (33.3) | 11 (33.3) | 0 (0.0) |
| Anorexia | 4 (26.7) | 4 (26.7) | 0 (0.0) | 18 (54.5) | 18 (54.5) | 0 (0.0) |
| Diarrhea | 13 (86.7) | 12 (80.0) | 1 (6.7) | 27 (81.8) | 26 (78.8) | 1 (3.0) |
| Epistaxis | 1 (6.7) | 1 (6.7) | 0 (0.0) | 2 (6.0) | 2 (6.0) | 0 (0.0) |
| Fatigue | 12 (80.0) | 12 (80.0) | 0 (0.0) | 22 (66.7) | 21 (63.6) | 1 (3.0) |
| Gastrointestinal hemorrhage | 1 (6.7) | 1 (6.7) | 0 (0.0) | 1 (3.0) | 1 (3.0) | 0 (0.0) |
| Hand-foot skin reactions | 11 (73.3) | 10 (66.7) | 0 (0.0) | 12 (36.3) | 11 (33.3) | 1 (3.0) |
| Liver dysfunction | 4 (26.7) | 4 (26.7) | 1 (6.7) | 25 (75.8) | 23 (69.7) | 2 (6.0) |
| Nausea | 12 (80.0) | 12 (80.0) | 0 (0.0) | 19 (57.6) | 19 (57.6) | 0 (0.0) |
- Citation: Ye HH, Ye JZ, Xie ZB, Peng YC, Chen J, Ma L, Bai T, Chen JZ, Lu Z, Qin HG, Xiang BD, Li LQ. Comprehensive treatments for hepatocellular carcinoma with tumor thrombus in major portal vein. World J Gastroenterol 2016; 22(13): 3632-3643
- URL: https://www.wjgnet.com/1007-9327/full/v22/i13/3632.htm
- DOI: https://dx.doi.org/10.3748/wjg.v22.i13.3632